ESC 365 - Increasing the class of foundational medication for heart failure is associated with improved prognosis in hospitalized patients with heart failure with reduced or mildly reduced ejection fraction

ESC Professional Premium Access

Increasing the class of foundational medication for heart failure is associated with improved prognosis in hospitalized patients with heart failure with reduced or mildly reduced ejection fraction

Session: Chronic heart failure treatment

Topic: Pharmacotherapy

Speaker: Doctor D. Maeda (Tokyo, JP)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Daichi Maeda

Juntendo University Graduate School of Medicine, Tokyo (Japan)

0 follower

4 more presentations in this session

Heart failure therapy in new onset heart failure versus chronic heart failure: an analysis of 90,383 patients from the Swedish Heart Failure Registry (SwedeHF)

Speaker: Ms A. Shahim (Stockholm, SE)

Ultra-fast remote up-titration of heart failure treatment: a safe, efficient and feasible protocol

Speaker: Doctor M. Massot (Toulouse, FR)

Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis

Speaker: Doctor R. Cordovez (Cebu City, PH)

Effect of diuretic down-titration on pulmonary congestion assessed by lung ultrasound when introducing sodium-glucose cotransporter 2 inhibitors

Speaker: Doctor M. Domingo (Badalona, ES)

Access the full session

Chronic heart failure treatment

Speakers: Doctor D. Maeda, Ms A. Shahim, Doctor M. Massot, Doctor R. Cordovez, Doctor M. Domingo

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources